Lergonix

Bilastine, the active ingredient in Lergonix, is an antihistamine presented as an ocular solution for eye drop use. It treats allergic conjunctivitis by relieving histamine‑mediated eye irritation in patients.

GNH USA supplies Lergonix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lergonix, containing bilastine, is used to manage ocular allergic conditions by blocking histamine effects. - Allergic conjunctivitis: reduces itching, redness, and swelling of the eye caused by histamine release. - Seasonal allergic eye symptoms: alleviates itching and tearing associated with pollen exposure. - Contact lens‑related allergic reactions: helps control irritation and redness in lens wearers.

Adverse reactions may occur with ocular use of bilastine.

Common Side Effects: - Transient eye irritation or burning sensation. - Bitter taste after administration. - Mild headache. - Dry eye sensation. - Blurred vision. - Mild redness.

Serious or Rare Side Effects: - Severe ocular pain or photophobia. - Vision loss or sudden visual disturbances. - Corneal ulcer or epithelial defect. - Anaphylactic reaction (rare). - Significant intra‑ocular pressure increase.

When using Lergonix, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Driving or operating machinery: be aware of possible visual disturbances. - Recent eye surgery: avoid use until cleared by the surgeon. - Contact with contaminated hands: ensure hands are clean before instillation. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Bilastine may interact with other substances that affect histamine pathways or ocular absorption.

Major Interactions (Avoid): - Systemic antihistamines: additive sedation or anticholinergic effects. - Monoamine oxidase inhibitors (MAOIs): potential enhancement of antihistaminic activity.

Moderate Interactions (Monitor Closely): - Alcohol: may increase drowsiness. - CYP3A4 inhibitors: could raise systemic exposure if absorbed. - Other ocular medications: may interfere with absorption; stagger dosing times.